Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4818286 | 0.90 | CTSK (0.39) | CTSKCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4818294 | 0.90 | CTSK (0.39) | CTSKCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4818625 | 0.90 | CTSK (0.39) | CTSKCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL15866143 | 0.86 | CTSK (0.40) | CTSKCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL6327607 | 0.85 | GPR88 (0.36) | CTSKCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL15268288 | 0.83 | CHRNB2 (0.38) | CTSKCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL19646813 | 0.83 | CHRNB2 (0.38) | CTSKCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1069362 | 0.82 | HDAC6 (0.33) | CTSKCA14HDAC6HDAC1HDAC2 | |
| SCHEMBL3711368 | 0.82 | CTSK (0.38) | CTSKCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4818893 | 0.81 | CTSK (0.36) | CTSKPDK2HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682139-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-06-20 | — | — | US | disclosed |
| US-20150265708-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-09-24 | — | — | US | disclosed |
| US-8999351-B2 | Lipids and compositions for the delivery of therapeutics | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2015-04-07 | — | — | US | disclosed |
| EP-1908759-B1 | 3,4-dihydro-3-amino-2H-1-benzopyrane and -benzothiopyrane derivatives as dopamine-beta-hydroxylase Inhibitors and methods of their preparation | BIAL PORTELA & CA SA (PT) | 2012-03-21 | — | — | EP | disclosed |
| US-20110311583-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| EP-1908760-B1 | Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation | BIAL PORTELA & CA SA (PT) | 2011-04-13 | — | — | EP | disclosed |
| EP-1911757-B1 | Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors | PORTELA & CA SA (PT) | 2011-03-02 | — | — | EP | disclosed |
| EP-1914233-B1 | Silyl-protected hydroxymethyl-carbamoylalkyl-ketones as intermediates in the preparation of dopamine-beta-hydroxylase inhibitors | PORTELA & CA SA (PT) | 2011-03-02 | — | — | EP | disclosed |
| US-20100286219-A1 | 1, 3-Dihydroimidazoles for Treating Cardiovascular Disorders | BIAL - PORTELA & CA S.A. (PT) | 2010-11-11 | — | — | US | disclosed |
| EP-2111262-A2 | 1,3-DIHYDROIMIDAZOLES FOR TREATING CARDIOVASCULAR DISORDERS | BIAL - Portela & Ca., S.A. (PT) | 2009-10-28 | — | — | EP | disclosed |
| EP-1911757-A2 | Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors | Portela & Ca., S.A. (PT) | 2008-04-16 | — | — | EP | disclosed |
| EP-1908760-A1 | Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation | Portela & Ca., S.A. (PT) | 2008-04-09 | — | — | EP | disclosed |
| EP-1908759-A2 | 3,4-dihydro-3-amino-2H-1-benzopyrane and -benzothiopyrane derivatives as dopamine-beta-hydroxylase Inhibitors and methods of their preparation | Portela & Ca., S.A. (PT) | 2008-04-09 | — | — | EP | disclosed |
| US-7259271-B2 | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2007-08-21 | — | — | US | disclosed |
| US-20070015730-A1 | Peripherally-Selective Inhibitors of Dopamine-ß-Hydroxylase And Method Of Their Preparation | PORTELA & C.A., S.A. (PT) | 2007-01-18 | — | — | US | disclosed |
| US-7125904-B2 | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2006-10-24 | — | — | US | disclosed |
| CN-1726211-A | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | PORTELA & CA SA (PT) | 2006-01-25 | — | — | CN | disclosed |
| US-20040142996-A1 | Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2004-07-22 | — | — | US | disclosed |
| WO-2004033447-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS PERIPHERALLY-SELECTIVE INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE | PORTELA & C.A., S.A. (PT) | 2004-04-22 | — | — | WO | disclosed |
| EP-1408038-A2 | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | Portela & Ca., S.A. (PT) | 2004-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142996-A1 | Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation | DBH, ADRB1, ADRB3 | CTSK 2589/4885CHRNB2 223/4885CHRNB4 242/4885 |
| US-20150265708-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | SGMS2, SGMS1, PHOSPHO1 | CTSK 2578/4885CHRNB2 2511/4885CHRNB4 2168/4885 |
| US-20070015730-A1 | Peripherally-Selective Inhibitors of Dopamine-ß-Hydroxylase And Method Of Their Preparation | DBH, PAH, TH | CTSK 3682/4885CHRNB2 436/4885CHRNB4 512/4885 |
| US-20110311583-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | SGMS1, SGMS2, PHOSPHO1 | CTSK 2525/4885CHRNB2 2387/4885CHRNB4 2184/4885 |
| US-20100286219-A1 | 1, 3-Dihydroimidazoles for Treating Cardiovascular Disorders | HTR1F, HTR1D, ADRB3 | CTSK 3438/4885CHRNB2 637/4885CHRNB4 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.